Pharmacy Council of India

Global Head And Neck Cancer Therapeutics Market Report 2022: Increasing Demand For Immunotherapy Treatment Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Pharmaceutical, Health, Oncology, Online, Cell, Large-cell lung carcinoma, Route, Nasal cavity, Hospital, Lymphoma, Therapy, Cancer, Neoplasm, Speech, Administration, Targeted therapy, Melanoma, Paranasal sinuses, Neck, Government, DNA, Head and neck cancer, Pharynx, Head, Immune system, Death, Patient, Exocrine gland, Injection (medicine), Pharmacy Council of India, Radiation, Mortality, Pharmacy, Hair loss, Pembrolizumab, Fatality, Market share, Larynx, Vaccine, Pharmaceutical industry, Immunotherapy

Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer.

Key Points: 
  • Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer.
  • Based on the Therapy Type, the Head and Neck Cancer Therapeutics Market is segmented into Chemotherapy, Immunotherapy, and Targeted Therapy.
  • Region-wise, the Head and Neck Cancer Therapeutics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA.
  • The North America segment registered the largest revenue share in the head and neck cancer therapeutics market in 2021.

Global COPD Drug Delivery Devices Market Report 2022-2027: Rise in Focus on Smart or Digital Inhalers for Administration of COPD Drugs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
General Health, Pharmaceutical, Health, Medical Devices, Online, Ansoff Matrix, Pharmacy Council of India, Market share, SWOT, USD, Porter's five forces analysis, Risk, Nebulizer, Growth, Inhaler, Pharmacy, Investment, Electron capture, COVID-19, Observation, Hospital, Market development, Geography, Retail, Risk management, Pharmaceutical industry

The Global COPD Drug Delivery Devices Market is segmented based on Product, Type, Distribution Channel, and Geography.

Key Points: 
  • The Global COPD Drug Delivery Devices Market is segmented based on Product, Type, Distribution Channel, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global COPD Drug Delivery Devices Market.
  • The analyst analyses the Global COPD Drug Delivery Devices Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global COPD Drug Delivery Devices Market.

Global Rare Disease Drugs Market Report 2022: A $147.12 Billion Market in 2021 - Analysis By Drug Type, Therapeutic Area, Patients, Route of Administration, Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Monday, December 12, 2022
Health, Pharmaceutical, Online, Rare disease, AbbVie, Infection, Pediatrics, Research report, Diagnosis, Takeda Pharmaceutical Company, Oral, Prevalence, Metabolism, Cancer, Bayer, Biogen, GlaxoSmithKline, Biopharmaceutical, Market share, Route of administration, Merck Group, Drug development, COVID-19, Pathology, Administration, Growth, Plasma protein binding, Novartis, Pharmacy Council of India, Safety, Neurology, Hospital, Pharmacy, Distribution, USD, Sanofi, Pharmaceutical industry, Dietary supplement, Medical device, Dentistry, Pfizer, Patient

According to the research report, the Global Rare Disease Drugs was valued at USD 147.12 Billion in the year 2021

Key Points: 
  • According to the research report, the Global Rare Disease Drugs was valued at USD 147.12 Billion in the year 2021
    The increasing focus on research activities and development of novel therapeutic drugs has facilitated the growth of the Rare Disease Drugs market.
  • The report presents the analysis of Rare Disease Drugs market for the historical period of 2017-2021 and the forecast period of 2022-2027.
  • The report analyses the Rare Disease Drugs Market by Therapeutic Area (Infectious Disease, Oncology, Neurology, Metabolic, Others)
    The report analyses the Rare Disease Drugs Market by Patients (Pediatric, Adults).
  • The report analyses the Rare Disease Drugs Market by Distribution Channel (Hospital & Retail Pharmacies, Online Pharmacies)..

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Dementia Drugs Market Predicted to Reach USD 19.7 Billion, Globally, by 2031 at 8.5% CAGR: Says Allied Market Research

Retrieved on: 
Monday, December 12, 2022
Online, Vascular dementia, Geriatrics, Cholinesterase, Conditional sentence, Diagnosis, Drug discovery, Hospital, Dementia, Parkinson's disease dementia, Prevalence, Patient, NMDA, Smoker, Research, COVID-19, Drug development, Pharmacy, Government, Combination, Investment, Growth, Receptor antagonist, Life expectancy, Distribution, Pharmacy Council of India, Consciousness, Medical device, Pharmaceutical industry, Alzheimer's disease

PORTLAND, Ore., Dec. 11, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Dementia Drugs Market by Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), by Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global dementia drugs industry generated $8.7 billion in 2021, and is anticipated to generate $19.7 billion by 2031, witnessing a CAGR of 8.5% from 2022 to 2031.

Key Points: 
  • However, strict government regulations related to product approval and high cost linked to R&D activity restrain the growth of dementia drugs industry.
  • Conversely, accelerated technological advancement in drug discovery techniques and high investment for drug development by the government are expected to offer lucrative opportunity for the dementia drugs market in future.
  • The outbreak of the Covid-19 pandemic had a positive impact on the global dementia drugs market, as it was reported that the pandemic caused a significant rise in the number of dementia patients.
  • Thus, increase in COVID-19 infection in patients with Alzheimer's disease increased the demand for dementia drugs during the pandemic.

Pancrelipase Market to Reach USD 2.7 Billion, Globally, by 2031 at 4.3% CAGR: Allied Market Research

Retrieved on: 
Monday, December 5, 2022
Online, Chronic pancreatitis, Pancreatic cancer, Cystic fibrosis, Patient, Prevalence, Hospital, Employment, Incidence, Pharmacy, Growth, Bromelain, Distribution, Pharmacy Council of India, Pharmaceutical industry, Dietary supplement, Geriatrics

PORTLAND, Ore., Dec. 4, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Pancrelipase Market by Application (Chronic Pancreatitis, Cystic Fibrosis, Others), by Age (Children, Adults and Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global pancrelipase industry was estimated at $1.8 billion in 2021, and is anticipated to hit $2.7 billion by 2031, registering a CAGR of 4.3% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chains, competitive scenarios, and regional landscapes.

Key Points: 
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • However, as the global situation started getting back to normalcy, the pancrelipase market also restored at a slow & steady pace.
  • By region, North America contributed to nearly three-fourths of the global pancrelipase market revenue, holding the major share in 2021.

Pancrelipase Market to Reach USD 2.7 Billion, Globally, by 2031 at 4.3% CAGR: Allied Market Research

Retrieved on: 
Monday, December 5, 2022
Online, Chronic pancreatitis, Pancreatic cancer, Cystic fibrosis, Patient, Prevalence, Hospital, Employment, Incidence, Pharmacy, Growth, Bromelain, Distribution, Pharmacy Council of India, Pharmaceutical industry, Dietary supplement, Geriatrics

PORTLAND, Ore., Dec. 4, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Pancrelipase Market by Application (Chronic Pancreatitis, Cystic Fibrosis, Others), by Age (Children, Adults and Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global pancrelipase industry was estimated at $1.8 billion in 2021, and is anticipated to hit $2.7 billion by 2031, registering a CAGR of 4.3% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chains, competitive scenarios, and regional landscapes.

Key Points: 
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • However, as the global situation started getting back to normalcy, the pancrelipase market also restored at a slow & steady pace.
  • By region, North America contributed to nearly three-fourths of the global pancrelipase market revenue, holding the major share in 2021.

Global Antacids Market will reach US$ 10.50 Billion in 2027

Retrieved on: 
Thursday, December 1, 2022
Online, Proton, COVID-19, Growth, Dosage form, Tablet, GlaxoSmithKline, Heartburn, OTC, Pharmacy, American College of Gastroenterology, Organization, Prescription, American College, Sanofi, Pfizer, Abbott Laboratories, Pharmacy Council of India, Acid neutralizing capacity, Patient, Indigestion, Aluminium, Information technology, Inflammation, Bayer, US, Hospital, Sodium bicarbonate, Ulcer, Gastroesophageal reflux disease, Research, Calcium, Stomach, Johnson & Johnson, Magnesium hydroxide, Obesity, Pharmaceutical industry, Fine chemical, Antacid

View original content:https://www.prnewswire.com/news-releases/global-antacids-market-will-rea...

Key Points: 
  • Global Antacids Market will reach US$ 10.50 Billion in 2027 According to the research.
  • Globally, antacids are widely used for treating ulcers, inflammation, dyspepsia discomfort, sore stomach, stomach acid indigestion, and stomach upset.
  • According to our research findings Antacids Market Size is likely to expand at a CAGR of 3.78% during 2022 " 2027.
  • But due to the rising demand for new antacids, the market will be growing in the coming years.

To Elevate Service Excellence, D2 makes Senior Leadership Promotions and Adds New Leaders

Retrieved on: 
Thursday, December 1, 2022
Growth, CFO, Specialty pharmacy, HUB, Market access, Pharmacy, ST, Hospital, Rede, Disease management, Pharmacy Council of India, Knowledge, PBM, Pharmaceutical Services Negotiating Committee, Distribution, Strategic planning, Pharmacist, Time-invariant system, Regulation, Express Scripts, Senior, Software as a service, Cancer Treatment Centers of America, Doctor of Pharmacy, Management, Walgreens, Medicaid, D2, Accreditation

ST. LOUIS, Dec. 01, 2022 (GLOBE NEWSWIRE) -- D2 Solutions is an innovative solution provider that helps empower healthcare stakeholders by leveraging SaaS technology with deep consulting expertise to eliminate key friction points in the marketplace to help drive and achieve better efficiency and improve patient results. As part of D2’s ongoing commitment to service excellence, D2 has made two key promotions and added additional resources to better meet client needs and position itself for expansive growth.

Key Points: 
  • As part of D2s ongoing commitment to service excellence, D2 has made two key promotions and added additional resources to better meet client needs and position itself for expansive growth.
  • D2 is excited to announce the promotion of Laura Reibenstein , PharmD, to the position of Chief Operating Officer.
  • Ms. Reibenstein has been with D2 since 2017, most recently serving as Senior Vice President, Accreditation, Regulatory & Specialty Operations.
  • Laura will be working to develop and strengthen the value D2 Solutions offered to clients, collaborating with senior leadership to propel our direction in alignment with our strategy, stated Dean Erhardt , D2 President & CEO.

Global Intranasal Drug and Vaccine Delivery Market Report 2022: Rising Prevalence of Respiratory and Neurological Diseases Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 22, 2022
Health, Pharmaceutical, Online, Investment, Degenerative disease, Geography, Pharmacy, SWOT, Ansoff Matrix, USD, Hospital, Pharmacy Council of India, Market development, Vaccination, Growth, Multi, Market share, Pain management, Risk, Vaccine, Pharmaceutical industry, Dose, Application

By Products, the market is classified into Liquid Delivery Device, Powder Delivery Device, and Pressurized Metered Dose Inhaler.

Key Points: 
  • By Products, the market is classified into Liquid Delivery Device, Powder Delivery Device, and Pressurized Metered Dose Inhaler.
  • The report presents a detailed Ansoff matrix analysis for the Global Intranasal Drug and Vaccine Delivery Market.
  • The analyst analyses the Global Intranasal Drug and Vaccine Delivery Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.